A Study to Evaluate the Pharmacokinetics (PK) and Safety of DUR-928 in Subjects with Impaired Kidney Function and Matched Control Subjects with Normal Kidney Function

Trial Profile

A Study to Evaluate the Pharmacokinetics (PK) and Safety of DUR-928 in Subjects with Impaired Kidney Function and Matched Control Subjects with Normal Kidney Function

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs DUR 928 (Primary)
  • Indications Renal failure
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors DURECT Corporation
  • Most Recent Events

    • 08 Aug 2017 According to a DURECT Corporation media release, status changed from recruiting to completed.
    • 10 May 2017 According to a DURECT Corporation media release, the company expects to complete this study shortly.
    • 03 Apr 2017 Planned number of patients changed from 45 to 18.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top